Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- iSpecimen Inc.iSpecimen Supports Hospital Validation of New Chemistry AnalyzeriSpecimen, a provider of human biospecimens, is supporting a hospital laboratory in the validation of a new chemistry analyzer for clinical use. For the project, iSpecimen identified a healthcare system already using the same analyzer and is coordinating the collection of more than 1,700 serum, plasma, cerebrospinal fluid (CSF), and urine specimens for use in the hospital's validation process.The specimens represent a broad range of...
- Silexion Therapeutics Announces Exercise of WarrantsSilexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of $0.2603 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-298137). The gross proceeds to the Company from the exercise of the warrants are expected to be $837,366.36, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about September 29, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.
- Nasus Pharma, Ltd.Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of OndansetronTopline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026
- Dianthus Therapeutics, Inc. NEW YORK andDianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual MeetingDianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place September 29 to October 2, 2026 in Orlando, Florida.
- Keros Therapeutics to Receive Additional Development Milestone Payment from Partner TakedaCompanies: Takeda Pharmaceutical CompanyKeros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (“MF”) and anemia on concurrent ruxolitinib therapy.
- Tokyo Lifestyle Co., Ltd. Strengthens Capital Structure Through Cash Investment and Debt-to-Equity ConversionTokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia, today announced that on September 10, 2026, its board of directors (the “Board”) approved two equity transactions designed to strengthen the Company’s capital structure. The transactions include a direct cash investment by the Company’s Representative Director and the conversion of outstanding shareholder-related debt into equity. Both issuances are scheduled to close on September 29, 2026.
- Zai Lab LimitedZai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)SHANGHAI & CAMBRIDGE, Mass., September 29, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) will be shared for the first time at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026, in Madrid.
- Neuropacs™ Corp.UF-Led Alzheimer’s Research Center Awarded $22 Million to Accelerate Discoveries; Neuropacs CSO David Vaillancourt to Play Key Scientific Leadership RoleGAINESVILLE, Fla., September 29, 2026--Neuropacs™ Corp. today announced that its Co-Founder & Chief Scientific Officer, Dr. David Vaillancourt, will serve as a key scientific leader in a $22 million National Institutes of Health grant supporting the University of Florida-led Alzheimer’s Disease Research Center (1Florida ADRC).
- NorthStar Medical Technologies, LLCNorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer TherapiesBELOIT, Wis., September 29, 2026--NorthStar Medical Technologies, LLC (NorthStar), the first commercial-scale producer of no-carrier-added actinium-225 (n.c.a. Ac-225) using electron-accelerator technology, today announced a multi-year growth capital facility of up to $185 million with Hercules Capital, Inc. (NYSE: HTGC) to support NorthStar’s continued growth and expansion.
- Teleflex IncorporatedTeleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ TechnologyWAYNE, Pa., September 29, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a
- Hospital Command Centers: Global Market Size, Share & Trends Analysis and Forecast (2026-2036)Growth is driven by smart hospital initiatives, AI, predictive analytics, cloud platforms, IoT and demand for real-time patient flow, bed capacity and resource management. North America leads the market, while Asia-Pacific is forecast to grow fastest.
- MENA Medical Semiconductor Memory Market Size, Trends, Competitive Landscape, and Forecast to 2032 | Digital Health and Next-Generation Memory Unlock Growth OpportunitiesExplore MENA demand-supply trends, growth drivers, competitive positioning, distributor networks, segment opportunities and market-entry strategies